Zogenix racing to FDA with abuse-resistant Zohydro; Emerald raises cash, launches virtual lab;

@FierceBiotech:  | Follow @FierceBiotech

@JohnCFierce: Interesting Porges note spotlights $GILD's 67% success rate in deals--95% success rate by $$$--since 2000. No doubt Sovaldi helped... | Follow @JohnCFierce

@DamianFierce: Oct. 2013: Seragon raises $30M Series A. July 2014: $RHHBY buys it for up to $1.7B. News | Follow @DamianFierce

@EmilyMFierce: Chikungunya: Tracing a Virus's Past to Predict its Future. Story from The Scientist | Follow @EmilyMFierce

Under assault by critics and facing serious competition from development rivals, San Diego-based Zogenix ($ZGNX) says it's racing ahead on the development of an abuse-deterrent version of the pain killer Zohydro. The biotech now says it can file a supplemental NDA by October, accelerating its timeline for returning to the agency. Release

The lab research company Emerald Therapeutics has raised new funding, bringing its total to $13.5 million. Emerald also has its first product: the Emerald Cloud Laboratory. The ECL is a "state-of-the-art life sciences laboratory that scientists can remotely access via the Internet." Release

> New York-based Retrophin has added $45 million in debt. Release

The heart disease specialist Cardio3 BioSciences has raised  €25 million ($34 million). Release

> Novato, CA-based Raptor Pharmaceutical struck agreements for $70 million in funding from HealthCare Royalty Partners and its affiliates in a private placement. Release

Medical Device News

@FierceMedDev: Muscle cell-powered 'bio-bot' could carry drugs. Story | Follow @FierceMedDev

@StacyALawrence: In obesity device race, ReShape lines up with FDA. Article | Follow @StacyALawrence

@VarunSaxena2: AHRQ report highlights government concern over chronic wound care, home healthcare. Story | Follow @VarunSaxena2

@MichaelGFierce: Nanoparticles designed to prevent cancer, aid bones. More from Laboratory Equipment | Follow @MichaelGFierce

@EmilyWFierce: Which med tech CEOs took home the biggest paychecks in 2013? Find out here: Feature | Follow @EmilyWFierce

> Intuitive Surgical kicks off da Vinci sales in Japan. Article

> Med techs Cerus, Amedica score $56M in debt. Story

> Canada to implement UDI based solely on international guidelines. Report

Pharma News

@FiercePharma: Once again, top-read on FP yesterday: Sex, bribes and videotape: Clandestine video of $GSK exec adds to China scandal. Article | Follow @FiercePharma

@TracyStaton: ICYMI: Here's @JohnCFierce's take on the Vertex VX-809/Kalydeco PhIII, including interview with CEO Jeff Leiden. Story | Follow @TracyStaton

@EricPFierce: ICYMI: This Indian pharma exec understands how to attain quality production & that many of his compatriots do not. More | Follow @EricPFierce

@CarlyHFierce: In case anybody missed this one, here are the top 5 vaccines by 2020. Feature | Follow @CarlyHFierce

> Not for sale, says new Actavis CEO. We're buying instead. Story

> Takeda COO Weber's reset plans include acquisitions, market expansion. More

> France aims to save big bucks by subbing unapproved Avastin for eye drug Lucentis. Article

Drug Delivery News

> Muscle cell-powered 'bio-bot' could carry drugs. Story

> Researchers aim to sneak antibiotics into bacteria via naturally occurring molecule. Article

> BMS recalls injectable warfarin, oral formulation unaffected. More

> MicroRNA delivery specialist Microlin Bio nears $30 million IPO. Article

> Targeted nanoparticles home in on myeloma and strengthen bones. Story

Diagnostics News

> Roche and New Zealand university launch lab team for Dx development and training. Article

> GE Healthcare's Alzheimer's imaging agent gains backing of key EU agency committee. News

> Report: Abbott is cutting diagnostics division jobs. More

> NIH keeps Corgenix Ebola Dx project running with new funding. Article

> Abcodia will license access to serum biobank for cardiovascular disease biomarker work. Story

Pharma Marketing News

> Facing threats from Purdue, Teva and Pfizer, Zogenix puts Zohydro follow-up into high gear. More

> The FDA should step up its own social-media action, NEJM researchers say. Report

> Study: Med students cozy with industry reps more likely to dole out branded drugs. More

> With a new IPF drug on its way, Boehringer backs a Discovery documentary on the lung disease. Story

> Now that it's FDA-approved, MannKind has to actually sell its inhaled insulin Afrezza. Article

> J&J, Pfizer in tug-of-war over ads for Infants' Advil. News

Suggested Articles

Akero's FGF21 analog beat placebo at reducing liver fat in patients with nonalcoholic steatohepatitis (NASH).

Amgen has become the latest biopharma to try to figure out the hit it may take to its pipeline timings amid the COVID-19 pandemic.

The database was locked at the end of February but will only be unblinded after the FDA has provided feedback.